2024年12月25日 · TNFSF10 (TNF Superfamily Member 10) is a Protein Coding gene. Diseases associated with TNFSF10 include Anaplastic Thyroid Carcinoma and Ameloblastoma. Among its related pathways are MIF Mediated Glucocorticoid Regulation and CASP8 activity is inhibited.

TRAIL gene transfer into cancer cells can efficiently suppress established tumour growth, without major side effects [42,134,135,136,137,138], even in metastatic prone cancers cells . Using a syngeneic mouse model, TRAIL retroviral-mediated gene transfer in the bone marrow was shown to induce tumour growth regression [ 140 ].

2019年8月23日 · TRAIL gene transfection can produce a “bystander effect” of tumor cell killing and provide a potential solution to TRAIL-based cancer therapy. In this review we focus on TRAIL gene...

TRAIL is a member of the TNF superfamily that induces tumor-selective cell death by engaging the pro-apoptotic death receptors DR4 and DR5. The antitumor potential of the TRAIL pathway has been targeted by several therapeutic approaches including recombinant TRAIL and TRAIL-receptor agonist antibodies among others.

2022年10月4日 · TRAIL kills many cancer cells, but does not induce apoptosis in most normal cell types, a discovery that led to the clinical development of TRAIL-receptors agonists. Clinical success of novel...

The apoptosis-inducing TRAIL gene caused significant changes in the biomechanics properties of Jurkat cells. Blocking the proteasome may be a way to sensitize hepatcellular carcinoma cells to TRAIL. TRAIL apoptotic pathway plays an important …

Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995--because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues.

TRAIL is a member of the TNF superfamily that induces tumor-selective cell death by engaging the pro-apoptotic death receptors DR4 and DR5. The antitumor potential of the TRAIL pathway has been targeted by several therapeutic approaches including recombinant TRAIL and TRAIL-receptor agonist antibodi …

2024年12月30日 · Given TRAIL's ability to selectively induce apoptosis in tumor cells, recombinant human TRAIL and TRAIL-receptor agonistic antibodies have been developed as anticancer therapeutics. These agents, classified as first-generation TRAIL receptor agonists (TRAs), have demonstrated promising preclinical antitumor activity by inducing apoptosis in ...

TRAIL has been implicated in the immune response to viral infections (good), and in the pathogenesis of multiple viral infections (bad). Furthermore, several viruses have evolved mechanisms to manipulate TRAIL signaling to increase viral replication (ugly).